Naslov
Effect of Empagliflozin on Cardiovascular Death in Subgroups by Age: Results from EMPA-REG OUTCOME®

Autori
RIDDERSTRÅLE, MARTIN ; TOURAL, ELVIRA ; FITCHETT, DAVID ; GILJANOVIC KÎS, SANJA ; WOERLE, HANS JURGEN ; MATTHEUS, MICHAELA ; ZINMAN, BERNARD ; INZUCCHI, SILVIO E.

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
American Diabetes Association ; 76th Scientific Sessions ; Abstracts: Diabetes 2016 ; 65(suppl 1): A289 / - , 2016

Skup
American Diabetes Association ; 76th Scientific Sessions, Abstracts in Diabetes 2016 ; 65(suppl 1):A289

Mjesto i datum
New Orleans (LA), Sjedinjene Američke Države, 10.06.2016. - 14.06.2016

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
EMPA-REG Outcome trial; empagliflozin; CV death; age-subgroups

Sažetak
In the EMPA-REG Outcome trial, empagliflozin (EMPA) given in addition to standard of care significantly reduced 3-point major adverse cardiovascular(CV) events (composite of CV death, non-fatal myocardial infarction, non fatal stroke), CV death and all- cause mortality vs. placebo (PBO) in patients with type 2 diabetes (T2DM) and high CV risk. Here we investigate the effect of age on the reduction in CV death with EMPA. Patients in EMPA-REG Outcome were randomized to receive EMPA 10 mg, EMPA 25 mg or PBO. CV death was analyzed in the pooled EMPA group vs. PBO in subgroups by baseline age (<65, 65 to <75, > 75 years). A total of 7020 patients were treated. Median observation time was 3.1 years. Mean (SD) age at baseline was 63.2 (8.8) years in the PBO group and 63.1 (8.6) years in the EMPA group. The benefit of EMPA vs. PBO on CV death was consistent across age categories (Figure). Across age subgroups, reported adverse events were consistent with the known safety profile of EMPA. EMPA, in addition to standard of care, reduced the risk of CV death in patients with T2DM and high CV risk irrespective of age.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA